ERYTECH Pharma Stock Forecast, Price & News

ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ERYTECH Pharma stock.
View analyst ratings for ERYTECH Pharma or view top-rated stocks.

What stocks does MarketBeat like better than ERYTECH Pharma?

Wall Street analysts have given ERYTECH Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ERYTECH Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a drop in short interest in August. As of August 31st, there was short interest totaling 34,500 shares, a drop of 70.5% from the August 15th total of 116,900 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the shares of the company are sold short.
View ERYTECH Pharma's Short Interest.

How has ERYTECH Pharma's stock price been impacted by Coronavirus (COVID-19)?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ERYP stock has increased by 14.7% and is now trading at $6.01.
View which stocks have been most impacted by COVID-19.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:

• Gil Beyen, Chief Executive Officer & Director
• Eric Soyer, Chief Operating & Financial Officer
• Stewart Craig, Chief Technical Officer
• Iman El-Hariry, Chief Medical Officer
• Jérôme Bailly, Chief Quality Officer & Deputy General Manager

Who are some of ERYTECH Pharma's key competitors?

Some companies that are related to ERYTECH Pharma include Talaris Therapeutics (TALS), Osiris Therapeutics (OSIR), Finch Therapeutics Group (FNCH), Molecular Partners (MOLN), Cellectis (CLLS), Acumen Pharmaceuticals (ABOS), MeiraGTx (MGTX), Aerie Pharmaceuticals (AERI), Gritstone bio (GRTS), DBV Technologies (DBVT), Passage Bio (PASG), Ambrx Biopharma (AMAM), Innate Pharma (IPHYF), Innate Pharma (IPHA) and CEL-SCI (CVM).
View all of ERYP's competitors.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (4.98%).

Which major investors are buying ERYTECH Pharma stock?

ERYP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL.

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $6.01.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $166.65 million and generates $4.25 million in revenue each year. The company earns $-83,730,000.00 in net income (profit) each year or ($4.55) on an earnings per share basis.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 206 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438 or via email at [email protected].